Compare · LYRA vs WST
LYRA vs WST
Side-by-side comparison of Lyra Therapeutics Inc. (LYRA) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LYRA and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $29.12B, about 639.7x LYRA ($45.5M).
- Over the past year, LYRA is down 89.9% and WST is up 41.7% - WST leads by 131.6 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- WST has more recent analyst coverage (15 ratings vs 7 for LYRA).
- Company
- Lyra Therapeutics Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.49-61.33%
- $306.12-1.10%
- Market cap
- $45.5M
- $29.12B
- 1M return
- +0.00%
- +23.98%
- 1Y return
- -89.93%
- +41.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 4
- Recent ratings
- 7
- 15
Lyra Therapeutics Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest LYRA
- SEC Form 25 filed by Lyra Therapeutics Inc.
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- SEC Form 4 filed by Palasis Maria
- SEC Form 4 filed by Cavalier Jason
- SEC Form 10-K filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- SEC Form DEFA14A filed by West Pharmaceutical Services Inc.
- SEC Form DEF 14A filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits